Introduction
============

Due to insufficiency of traditional end points (which are mainly focused on the biologic and physiologic outcomes) in capturing the effects of interventions on patients' health-related quality of life (HRQoL), a growing interest has emerged during the past decades for assessing determinant factors of patients' HRQoL, especially in chronic diseases \[[@B1]\]. Diabetes mellitus is one of these chronic diseases that involve people of all ages and races. It is considered as one of the most common chronic diseases in approximately all countries, and its prevalence continues to increase mainly due to the changes in lifestyles resulting in physical inactivity, and increased obesity \[[@B2]\]. It was estimated that diabetes affected 285 million adults (20--79 years) worldwide in 2010, and this figure will increase to 439 million adults by 2030 \[[@B2]\].

Diabetes is associated with higher risk of some macro and microvascular complications. As result, these complications cause mortality rate among diabetic patients to be about twice as much as that of non-diabetic individuals of a similar age \[[@B3],[@B4]\]. Moreover, patients with these complications have lower HRQoL than diabetes patients without the complications \[[@B5],[@B6]\].

In Iran, prevalence of diabetes increased from 7.7% in 2005 to 8.7% in 2007 \[[@B7],[@B8]\]. In addition, it was estimated that annual direct medical cost of diabetes is roughly US\$ 113 million and direct medical cost in patients with diabetes is about 3 times higher than general population in the country \[[@B9]\]. High prevalence of diabetes and its related complications have attracted the research and policy concern in the country over last few years. In response to this policy concern, a considerable body of literature has been emerged to evaluate HRQoL and its determinants in diabetic patients. These studies aimed to improve HRQoL in people with diabetes by providing evidence for informed decision-making. However, differences in the research questions, tools and population among these individual studies make it difficult to reach an obvious answer applicable for policy making purposes. In response to this, conducting a systematic review of individual studies to make the available evidences more accessible for policy-making is common in medical researches.

In this course, the current systematic review was conducted to describe the latest available information about HRQoL in people with diabetes in Iran. Specifically, this review aimed to investigate how HRQoL was measured in Iranian diabetic population, what were the main methodological flaws of these studies, and which factors were mainly associated with HRQoL in people with diabetes.

Method and materials
====================

Literature search
-----------------

A systematic literature search was independently conducted in March 2012 to review the studies which evaluated HRQoL among people with diabetes in Iran. The results of this literature search were independently verified and updated in June 2012. Studies published up to May 2012 were included in the review. National (SID, Magiran) and international databases (Pubmed, Medline, Web of Science, CINAHL, Scopus, PsycINFO and ERIC) were searched through following search terms: \["diabetes" AND "quality of life" AND "Iran"\]. Moreover, we searched Google for extra Persian publications. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B10]\].

Selection of studies
--------------------

Five exclusion criteria were applied: (1) the study did not investigate HRQoL in people with diabetes, (2) the study did not provide any data about HRQoL among study population (e.g., the study was related to instrument development in patients with diabetes); (3) the study was a review article; (4) the study was not a journal article (e.g., conference abstracts and dissertations); (5) the study was not applied to the Iranian population.

The initial search resulted in 214 documents. After excluding duplicates and non-relevant studies, 59 articles were selected for full text examination. The reference lists of these 59 documents were manually searched. In total, 46 studies were included for the review (Figure [1](#F1){ref-type="fig"}). In cases where multiple publications were produced from a single study, the paper with most comprehensive data was included.
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Data extracted from the selected studies are included, among others: year of publication, the location (or province) and the year the studies were conducted, study design, sample size, type of diabetes, age range of the sample, duration of diabetes, HRQoL measurement tool used, main predictors of HRQoL, and statistical methods used for analysis.

Results
=======

General characteristics
-----------------------

The characteristics of 46 eligible studies \[[@B11]-[@B56]\] for this review are shown in Table [1](#T1){ref-type="table"}. First study was published in year 2003 and since then there were few publications per year on the topic, with a peak in the publications in 2011 (Figure [2](#F2){ref-type="fig"}). HRQoL in people with diabetes was investigated in 20 out of 30 provinces of the country. 17 out of 46 studies were conducted in two provinces (Tehran & Hormozgan). Sample sizes across the studies ranged from 27 to 387 participants. Majority of the studies (76%) were published in a national Persian language journal. Cross-sectional design was the dominant design in the studies (N=32). In terms of type of diabetes, five studies included only people with type 1 diabetes and 23 studies covered only type 2 diabetic patients. In the remaining studies, there was a combination of type1, type2, and non-diabetes people in the sample. The age of participants ranged from 10 to 75 years old. In most studies, women constituted the majority of the study participants.

###### 

Characteristics of the studies included in the review

  **First author**                       **Data year**   **Language**   **Province**            **Main interest variable**            **Study design**              **Sample characteristics**                **HRQoL assessment**   **Statistical analysis**                                                                                                                                                         
  -------------------------------------- --------------- -------------- ----------------------- ------------------------------------- ----------------------------- ----------------------------------------- ---------------------- -------------------------- -------------------------------------------------------- ------ ----------------------------------------------------------------- ------------------- ---
  Aghamolaei T, 2003 \[[@B11]\]          \-              English        Hormozgan               Predictors of HRQoL                   Cross sectional               Type 2 (100)                              80                     32-72                      58.8                                                     5.8    WHOQOL-BREF                                                       Generic             U
  Aghamolaei T, 2005 \[[@B12]\]          \-              Persian        Hormozgan               Health education                      Quasi-experimental            Type 2 (100)                              71                     \-                         59.2                                                     6.0    WHOQOL-BREF                                                       Generic             U
  Ahari SS, 2008 \[[@B13]\]              2004            Persian        Ardebil                 Type 2 diabetes                       Cross-sectional               Type 2 (100)                              110                    \-                         66.4                                                     8      SF-36                                                             Generic             U
  Ahmadi A, 2011 \[[@B14]\]              2008            Persian        Chaharmahal Bakhtiari   Predictors of HRQoL                   Cross-sectional               Type 2 (100)                              254                    30-65                      59                                                       7.4    Developed by research team                                        Specific            A
  Alavi A, 2010 \[[@B15]\]               2008            Persian        Chaharmahal Bakhtiari   Type 1 diabetes                       Historical cohort             Type 1 (14.5), non-diabetes (85.5)        152                    8-18                       52.4 in diabetes group                                   NA     PedSQL                                                            Generic             U
  Alavi NM, 2004 \[[@B16]\]              2003            Persian        Tehran                  Predictors of HRQoL                   Cross-sectional               Type 1 (13),Type 2 (87)                   104                    \>18                       65                                                       9.7    Developed by research team, Well Being Index                      Specific, generic   U
  Bagheri H, 2005 \[[@B17]\]             NA              Persian        Semnan                  Micro-& macrovascular complications   Cross-sectional               Type 2 (100)                              150                    35-65                      NA                                                       NA     Audit of Diabetes Dependent Quality of Life                       Specific            U
  Baghianimoghadam MH, 2007 \[[@B18]\]   NA              Persian        Yazd                    Health education                      Quasi-experimental            Type 2 (100)                              120                    25-75                      59                                                       9.87   SF-20                                                             Generic             U
  Bazzazian S, 2010 \[[@B19]\]           NA              Persian        Tehran                  Coping strategies                     Cross-sectional               Type 1 (100)                              300                    18-30                      57.3                                                     NA     D-39                                                              Specific            A
  Borzou SR, 2010 \[[@B20]\]             NA              Persian        Hamedan                 HRQoL level                           Cross-sectional               Type 2 (100)                              165                    NA                         67.3                                                     NA     SF-36                                                             Generic             U
  Delvarianzadeh M, 2006 \[[@B21]\]      NA              Persian        Semnan                  Diet consultation                     RCT                           Type 2 (100)                              144                    35-65                      67.8                                                     NA     SF-36                                                             Generic             U
  Farahani TS, 2010 \[[@B22]\]           2007            Persian        Tehran                  Age and sex                           Cross-sectional               Type 1 (100)                              70                     11-18                      52.1                                                     2.23   Diabetes Quality of Life for Youth                                Specific            U
  Ghanbari A, 2004 \[[@B23]\]            2000            Persian        East Azerbaijan         Predictors of HRQoL                   Quasi-experimental            Type 2 (100)                              137                    NA                         86.1                                                     NA     NA                                                                Generic, specific   A
  Ghanbari A, 2004 \[[@B24]\]            NA              Persian        Gilan                   Type 2 diabetes                       Cross-sectional               Type 2 (51.1), non-diabetes (48.9)        176                    \>40                       78.8% (diabetic group), 55.8% (non-diabetic group)       NA     SF-36, SWED-QUAL                                                  Generic             A
  Ghanbari A, 2005 \[[@B25]\]            2000            English        East Azerbaijan         Predictors of HRQoL                   Cross-sectional               Type 2 (100)                              117                    \>35                       85.5                                                     NA     SWED-QUAL, diabetes-specific quality-of-life scale                Generic, specific   A
  Ghavami H, 2005 \[[@B26]\]             2003-2004       Persian        West Azerbaijan         Continious care                       Quasi-experimental            Type 2 (100)                              74                     40-65                      NA                                                       NA     Developed by research team in Iran (Alavi NM)                     Specific            U
  Haririan H, 2009 \[[@B27]\]            2007            Persian        East Azerbaijan         Aspects of HRQoL                      Cross-sectional               Type 2 (100)                              150                    20-\>60                    61.33                                                    NA     SF36+Swed- QUAL, a diabetes-specific questionnaire                Generic, specific   A
  Hashemi Hefzabad F, 2011 \[[@B28]\]    NA              English        Isfahan                 Diabetes impact on HRQoL              Cross-sectional               Diabetes (50), non-diabetes (50)          204                    20-60                      52% in both groups.                                      NA     Hanestad & Albrektsen's Attitude to Quality of Life               Generic             U
  Heidari M, 2007 \[[@B29]\]             2004-2005       Persian        Zanjan                  Empowerment model                     Quasi-experimental            Type 1 (100)                              47                     11-20                      \-                                                       \-     \-                                                                \-                  U
  Jafari P, 2011 \[[@B30]\]              NA              English        Fars                    Impact of type 1 diabetes on HRQoL    Cross-sectional               Type 1 (32), healthy (68)                 294                    8-18                       56.4% in diabetes and 53% in healthy group.              NA     PedsQL™ 4.0 Generic Core Scales, PedsQL™ 3.0 Diabetes Module      Generic, specific   A
  Jahanlou AS, 2007 \[[@B31]\]           2006            Persian        Hormozgan               Smoking                               Cross-sectional               Type 2 (100)                              125                    NA                         NA                                                       NA     WHOQOL-BREF 26                                                    Generic             U
  Jahanlou AS, 2008 \[[@B32]\]           2007            Persian        Hormozgan               Glycemic control                      Cross-sectional               Type 2 (100)                              110                    27-72                      66.9                                                     6.33   WHOQOL-BREF 26                                                    Generic             U
  Jahanlou AS, 2011 \[[@B33]\]           2007            English        Hormozgan               Education                             Cross-sectional               Type 2 (100)                              256                    27-72                      67.5                                                     6.33   WHOQOL-BREF 26                                                    Generic             U
  Jahanlou AS, 2011 \[[@B34]\]           2006            English        Hormozgan               HbA1c                                 Cross-sectional               Type 1 (11.8), Type 2 (88.2)              76                     NA                         60.5                                                     NA     WHOQOL-BREF 26, Iranian Diabetics' Quality of Life                Generic, specific   U
  Jahanlou AS, 2011 \[[@B35]\]           2007            English        Hormozgan               \-                                    Cross-sectional               Type 2 (100)                              387                    27-72                      51.9                                                     5.83   WHOQOL-BREF 26, Iranian Diabetics' Quality of Life                Generic, specific   U
  Kakhaki AD, 2006 \[[@B36]\]            2004            Persian        Tehran                  Predictors of HRQoL                   Cross-sectional               Type 1 (15.3), Type 2 (84.7)              131                    18-65                      60.3                                                     6.10   SF-36                                                             Generic             U
  Kasbakhi MS, 2008 \[[@B37]\]           2008            Persian        Mazandaran              Type 2 diabetes                       Case--control                 Type 2 (48.3), non-diabetes (51.7)        145                    NA                         90% in diabetic group and 81.3% in non-diabetic group.   NA     SF-36, SWED-QUAL                                                  Generic             U
  Kermansaravi F, 2012 \[[@B38]\]        2011            Persian        Sistan & Baluchestan    Predictors of HRQoL                   Cross sectional               Type 1 (100)                              100                    10-18                      47                                                       3.5    Diabetes quality of life youth                                    Specific            U
  Khaledi S, 2011 \[[@B39]\]             2009            Persian        Kordestan               Predictors of HRQoL                   Cross-sectional               Type 2 (100)                              198                    \>18                       83.8                                                     NA     SF-36                                                             Generic             U
  Khamseh MA, 2011 \[[@B40]\]            2009-2010       Persian        NA                      Aspects of HRQoL                      Cross-sectional               Type1 (100)                               150                    12-30                      49.3                                                     8.97   Developed by research team                                        Specific            A
  Nejatisafa, 2008 \[[@B41]\]            2005            Persian        Tehran                  HbA1c                                 Cross sectional               Type 1 (4), Type 2 (96)                   100                    18-65                      68.0                                                     9      WHOQOL-BREF                                                       Generic             A
  Peymani M, 2006 \[[@B42]\]             2005            Persian        Tehran                  Neuropathy                            Cross sectional               Type 1, Type 2                            304                    \>18                       76.1                                                     NA     Developed by research team                                        Specific            A
  Peymani M, 2007 \[[@B43]\]             2004-2005       Persian        Tehran                  Cardiovascular disease                Cross sectional               Type 1, Type 2                            302                    \>18                       76.1                                                     NA     Developed by research team                                        Specific            A
  Peymani M, 2008 \[[@B44]\]             2005            Persian        Tehran                  Retinopathy                           Cross sectional               Type 1, Type 2                            178                    \>18                       75.8                                                     NA     Developed by research team                                        Specific            A
  Rakhshandehru, 2006 \[[@B45]\]         2001-2002       Persian        Tehran                  Health education                      Quasi-experimental            Type 2 (100)                              44                     40-65                      45.5                                                     NA                                                                       Specific            U
  Rasouli D, 2011 \[[@B46]\]             2008            Persian        Tehran                  The predictors of HRQoL               Cross sectional               Patients with diabetic foot ulcer (100)   120                    \>45-65\<                  40.0                                                     NA     Diabetic foot scale questionnaire                                 Specific            U
  Safavi M, 2011 \[[@B47]\]              2009-2010       English        Ardebil                 Health education                      Randomised controlled trial   Type 2 (100)                              123                    30-70                      50.8% (experiment), 51.6% (control)                      NA     Farrell and Grant quality of life questionnaire                   Generic             U
  Sanjari M, 2011 \[[@B48]\]             \-              English        Kerman                  Foot ulcer                            Case--control                 Type 1 (11.4), Type 2 (88.6)              132                    \-                         37.9                                                     10.9   SF-36                                                             Generic             A
  Sayadi N, 2011 \[[@B49]\]              2007            Persian        Khuzestan               Open heart surgery                    Case--control                 Type 2 (38.8), non-diabetes (61.2)        80                     35-75                      65% (diabetic), 33% (non-diabetic)                       4.3    SF-36                                                             Generic             U
  Shahrjerdi S, 2009 \[[@B50]\]          2008            Persian        Markazi                 Physical excercise                    Quasi-experimental            Type 2 (100)                              27                     \>35                       100                                                      5.3    SF36, General Health Questionnaire                                Generic             U
  Shareh H, 2012 \[[@B51]\]              \-              Persian        Fars                    Perceived social support              Cross sectional               Type 2 (100)                              50                     NA                         NA                                                       NA     Multidimensional Scale of Perceived Social Support, WHOQOL-BREF   Generic             A
  Taghdisi MH, 2012 \[[@B52]\]           2009            English        Golestan                Health education                      Quasi-experimental            Type 2 (100)                              78                     NA                         79.5                                                     NA     WHOQOL                                                            Generic             U
  Timareh M, 2012 \[[@B53]\]             \-              Persian        Kermanshah              Predictors of HRQoL                   Cross sectional               Type 1 (4), Type 2 (96)                   350                    \>18                       58.3                                                     NA     SF-36                                                             Generic             U
  Vares Z, 2010 \[[@B54]\]               2006            Persian        Isfahan                 Predictors of HRQoL                   Cross sectional               Type 1 (18.4), Type 2 (81.6)              310                    \>18                       74                                                       10.9   Iranian Diabetes Quality of Life questionnaire                    Specific            A
  Vazirinejad R, 2010 \[[@B55]\]         2007            Persian        Kerman                  Diabetes                              Historical cohort             Diabetes (45.1), non-diabetes (54.9)      224                    \<30-\>60                  76.3                                                     8.0    SF-36                                                             Generic             U
  Yekta Z, 2011 \[[@B56]\]               2009-2010       English        West Azerbaijan         Foot ulcer                            Cross-sectional               Type 2 (100)                              250                    \-                         61.6                                                     7.7    SF-36                                                             Generic             A
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HRQoL instruments
-----------------

Regarding the instrument used to measure HRQoL, 17 different instruments were used in the studies. 25 studies used a generic measure, 13 studies used a disease-specific instrument and 7 studies applied both generic and disease-specific instruments among the study population. 14 studies used the Short Form Health Survey (SF-36) and 10 studies employed WHO quality of life instruments (WHOQOL) to evaluate HRQoL in patients with diabetes. In 10 studies an Iranian questionnaire, developed by authors or research teams of those studies or adapted from other Iranian researchers, were applied.

HRQoL in diabetes patients vs. non-diabetes
-------------------------------------------

Six studies, which examined the effect of diabetes on HRQoL, compared HRQoL in people with and without diabetes and reported negative effects of both type 1 and type 2 diabetes on HRQoL.

The effects of interventions
----------------------------

A total of 12 studies examined the effects of an intervention on HRQoL in people with diabetes. All studies, but one, evaluated the effects of educational interventions on HRQoL in people with diabetes and demonstrated improvements in HRQoL caused by these interventions.

Diabetes-related complications
------------------------------

Six studies mainly examined the effects of diabetes-related complications on HRQoL in patients with diabetes and reported negative effects of these complications on HRQoL. In addition, among remaining studies, 9 studies included these complications as a predictor of HRQoL and found that these complications were associated with lower HRQoL.

Other predictors of HRQoL
-------------------------

Association between HRQoL and some demographic, socioeconomic and clinical predictors were examined in the most studies. Except one study, all the other studies found a negative association between age and HRQoL. Moreover, in all studies except one, females had lower HRQoL than males. Better socioeconomic status (including income, education, employment) of individuals and/or their family was associated with better HRQoL. Better HRQoL was reported for married compared to non-married (single, widow) people. People with higher HbA1c generally had lower HRQoL. There were negative associations between blood pressure, blood lipid and HRQoL. Lower level of HRQoL was found among people with higher BMI. While most studies found a negative association between HRQoL and duration of diabetes, two studies reported a positive association. Smokers had worse HRQoL than their non-smoker counterparts. Two studies examined rural/urban disparities in HRQoL, but their results were not consistent, showing opposite results. In general, patients who were under diet treatment had better HRQoL than patients on drug or/and insulin therapies.

Discussion
==========

To our knowledge, for the first time, the current study has reviewed the results of 46 identified studies examining HRQoL among the Iranian patients with diabetes. The findings of this review showed that generally people with diabetes have worse HRQoL than their healthy counterparts. In addition, the findings indicated that diabetes-related complications have a significant negative impact on HRQoL among the diabetic patients in Iran. In general, associations between covariates and HRQoL in the reviewed Iranian studies were in line with their international counterparts.

The reviewed studies suffer from major methodological and reporting flaws which affected quality of their findings and limit their validity and generalizability. The reviewed studies mainly applied a nonrandom sampling method leading to possible selection bias. Moreover, calculation of sample size was unclear in the majority of the studies. Furthermore, while most studies were observational, univariate analysis was the main statistical approach used for data analysis and minimum effort was done to control for any imbalance in the covariates leading to potential confounder and selection biases. Among studies which employed multivariate analysis, some of the main confounding factors (such as diabetes-related complications and duration of diabetes) were not controlled for, raising possibility of confounder bias. In addition, these studies didn't explain their limitations adequately and did not comment on the potential biases in their reported results. Although, generic instruments were used by the most studies, limitations of these instruments in capturing HRQoL in patients with diabetes were not fairly explained. Moreover, several studies failed to validate the instruments before putting to use in a new population and only referred to application of the instruments in a diabetic population in other countries or a general population in Iran. It seems that similar to few other settings \[[@B57]\], Iranian researchers have used the instruments applied in other studies without worrying about their content.

The results of the current review should be interpreted in light of few limitations. Firstly, although Persian databases used in this review consisted majority of the articles published nationally, there is a possibility that some studies may not be included in these databases. Secondly, as a wide range of instruments were used in the reviewed studies and the transparency of reported results was limited, it was not possible to apply statistical methods such as meta-analysis to test association between the covariates and HRQoL. Increasing the number of studies applying the same instrument and improving transparency of reporting results may make it possible to conduct a meta-analysis in future.

The previous systematic reviews mainly have focused on evaluating and comparing measurement properties of instruments used in examining HRQoL among diabetes patients \[[@B57]-[@B61]\]. In a review of HRQoL studies among people with diabetes in Nordic countries, Wandell \[[@B62]\] found that diabetes had a negative effect on HRQoL and being at older age, having diabetes-related complications, having lower socioeconomic status, being female and having weaker control of clinical risk factors were associated with lower HRQoL. These findings are comparable to the findings of the current review.

In conclusion, growing interests in evaluating HRQoL among people with diabetes were observed in Iran over the last decade. The findings of this review showed that people with diabetes had a lower HRQoL than healthy people. The findings also indicated that better socioeconomic status and better control of cardiovascular risk factors were associated with better HRQoL among the patients with diabetes. The reviewed studies suffer from major methodological and reporting flaws which limit the validity and generalizability of their findings.
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